Chief Executive Officer
Marc Beer is the Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR). Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating often fatal, rare diseases. Marc took the company public in October 2010. The Company’s first marketed product, JUXTAPID™ (lomitapide) was approved by the U.S. Food and Drug Administration in December 2012. Marc brings over 20 years of development and commercialization experience in biotechnology, pharmaceuticals and diagnostics. In April 2000, Marc became the founding CEO of ViaCell (VIAC), a biotechnology company specializing in the collection, preservation, and development of umbilical cord blood stem cells, and over a period of seven years led the company from its inception to a rapidly growing and robust commercial organization. Under Marc's leadership, the company grew to more than 300 employees, went public in 2005 and was ultimately acquired in 2007 by PerkinElmer (PKI). Prior to founding ViaCell, Marc held various positions within Genzyme (GENZ), most recently as Vice President of Global Marketing where he was responsible for the commercial launch of several products addressing orphan disease populations on a global scale. Prior to Genzyme, he held a variety of sales and marketing roles in the pharmaceutical and diagnostic divisions of Abbott Laboratories (ABT). He also was a former member of the Mass Life Science Board of the Commonwealth of Massachusetts. Marc serves on the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Board. He is chairman of the board of directors of Good Start Genetics, Inc. and Minerva Pharma; Strategic Consultant to OvaScience; a member of the Graduate Studies and Research Advisory Council of Notre Dame University and a board member of the Joe Andruzzi Cancer Foundation. Marc holds a B.S. from Miami University (Ohio).
Chief Regulatory Officer
Martha Carter was appointed Chief Regulatory Officer of Aegerion in February 2011, bringing over 30 years of regulatory affairs experience in prescription and over-the-counter drugs, biologics, biotechnology products, and medical devices. Prior to joining Aegerion, Martha was Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc. where she was responsible for the company's worldwide regulatory and quality functions. Prior to this role, she was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to that, Martha was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. In this role, she led the company's regulatory and quality control functions for both commercial and investigational drug products. Martha is a Fellow of the Regulatory Affairs Professionals Society, and is a past President and Chairman of the Board. She is also a former member of the Editorial Advisory Board for Applied Clinical Trials and BioPharm. Martha holds a B.A. in Biology from Northeastern University.
Anne Marie Cook
Senior Vice President, General Counsel and Secretary
Anne Marie Cook was appointed Senior Vice President, General Counsel and Secretary in December 2011. Ms. Cook was most recently a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate). There she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property licenses. She also provided general legal support in connection with the research, development and commercialization of pharmaceutical products. Prior to joining Choate, Ms. Cook was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc. Prior to that, she was Vice President, Chief Corporate Counsel, at Biogen Idec Inc.
Chief Financial Officer
Mark Fitzpatrick was appointed Chief Financial Officer in April of 2011. He brings over 15 years of financial management experience in both public and private companies. He was most recently Vice President, Chief Financial Officer and Assistant Secretary at Proteon Therapeutics, Inc. Prior to his role at Proteon, Mr. Fitzpatrick was Vice President and Chief Financial Officer, Treasurer and Assistant Secretary with RenaMed Biologics, Inc. He also held CFO positions with Dynogen Pharmaceuticals, WorldStreet Corporation and Diacrin. He previously was a senior auditor with Arthur Andersen & Co. Mr. Fitzpatrick earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987, and holds a B.S. in Accounting from Boston College.
President, U.S. and International and Global Supply
Craig Fraser was appointed President, U.S. Commercial and Global Manufacturing and Supply Chain in September 2012. Prior to that appointment, Craig was President, U.S. at Aegerion. Before joining Aegerion, Mr. Fraser was Vice President, Global Disease Areas at Pfizer Inc. responsible for the commercial development and global marketing for the Specialty Cardiovascular, Anti-Bacterial, Anti-Fungal, Gastrointestinal and Anti-Viral disease areas, where he managed a portfolio of six products totaling over three billion dollars in revenue and multiple new products in development. He was charged with establishing the company's future specialty cardiovascular business including commercial inputs for the rare disease lipid market. Prior to Pfizer, Mr. Fraser was Vice President and Global Business Manager at Wyeth, where he led the institutional/infectious disease business. Before that, Mr. Fraser held several commercial positions at Johnson & Johnson, most recently as Vice President, Commercial Operations and Oncology Sales and Marketing. Previously, he was Gastroenterology Franchise lead as well as National Sales Director of the Immunology and Cardiovascular business units at Centocor, a start-up biotech and diagnostic company focused on monoclonal antibody-based technology.
Mark Sumeray, MD, MS, FRCS
Chief Medical Officer
Dr. Sumeray brings development, regulatory and medical affairs experience with cardiovascular drugs such as Plavix®, apixaban, Avapro®/Avalide®, and Angiomax® to Aegerion. Dr. Sumeray was most recently Vice President Cardiovascular/Metabolics U.S. Medical, at Bristol-Myers Squibb. In this role, he was responsible for U.S. medical strategy for the CV and metabolics medical strategy teams, including implementation across the medical affairs function working collaboratively with marketing, sales, global clinical research and health outcomes. Prior to this role, Dr. Sumeray held several positions of increasing responsibility within The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President Medical Business Development, and Vice President Clinical Development and Head of Medical Science. Prior to that, Dr. Sumeray was worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson.
Senior Vice President, Human Resources
Mary Weger was appointed Senior Vice President, Human Resources in December, 2011. Mary brings over 30 years of Human Resource experience, eleven of which has been within the biopharmaceutical industry. Prior to joining Aegerion, Mary was Senior Vice President, Global Clinical Development Strategy & Effectiveness at Celgene Corporation. Prior to this appointment, she held the position of Senior Vice President, Global Human Resources at Celgene where she played an instrumental role in helping to build Celgene globally from a company with 150+ employees to a world-wide organization with revenue of over 4 billion and operations in over 30 countries. Prior to Celgene, Mary held positions of increasing responsibility at Kraft Foods Nabisco. She received her Masters certificate and Black Belt in Six Sigma in 2011 from Villanova University and also possesses a MA in Human Resource Management as well as having completed the Executive Human Resources program at Michigan University. Mary currently serves on the Board of Family Promise, a non-profit organization addressing the needs of homeless families.